Compendia Bioscience Co-Founder to Present Gene Fusion Breakthrough at AACR; Dr. Arul Chinnaiyan Will Present Breakthrough Discovery in Prostate Cancer Made Using Oncomine.ANN ARBOR Ann Arbor, city (1990 pop. 109,592), seat of Washtenaw co., S Mich., on the Huron River; inc. 1851. It is a research and educational center, with a large number of government and industrial research and development firms, many in high-technology fields such as , Mich. -- The co-founder of Compendia com·pen·di·a n. A plural of compendium. Bioscience, Arul Chinnaiyan, M.D., Ph.D., will present the recent breakthrough discovery in prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. of recurrent gene fusions in the large majority of patients to the American Association of Cancer Research Annual Meeting in Washington, D.C., today. This discovery was initiated using outlier outlier /out·li·er/ (out´li-er) an observation so distant from the central mass of the data that it noticeably influences results. outlier an extremely high or low value lying beyond the range of the bulk of the data. analysis techniques within Oncomine, Compendia's unique oncology microarray database and analysis system. Oncomine has been a favorite tool of the academic oncology research community for the past 5 years and has more than 7,500 academic users. The technology has recently been licensed from the University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries. to Compendia to serve the biotechnology and pharmaceutical oncology research markets. "I look forward to presenting our findings regarding prostate gene fusions to the very distinguished audience at AACR AACR American Association for Cancer Research AACR Anglo-American Cataloging Rules AACR Australasian Association of Cancer Registries AACR African Armed Conflicts Resolved ," said Dr. Chinnaiyan. "This discovery is illustrative of the power of Oncomine -- a microarray database with unparalleled breadth and depth of tumor biology data and equally sophisticated analysis tools. We fully expect that Compendia's commercial customers will make similarly novel discoveries using this toolset." About Compendia Bioscience, Inc. Compendia Bioscience advances drug target and biomarker discovery through powerful molecular oncology tools, data, and analysis software. The Company's flagship product, Oncomine(TM), unifies and mines thousands of molecular oncology profiles, enabling researchers to assess target and pathway activity online in seconds. For additional information, please visit the Company's Web Site at www.compendiabio.com and the Oncomine Web Site at www.oncomine.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion